Premium
[P2–246]: NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER's DISEASE AND TAUOPATHIES
Author(s) -
Höglund Kina,
Cicognola Claudia,
Portelius Erik,
Brinkmalm Gunnar,
Zheng Zhentao,
Hansson Oskar,
Zetterberg Henrik,
Ye Keqiang,
Blennow Kaj,
Gobom Johan
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.898
Subject(s) - monoclonal antibody , tau protein , chemistry , microbiology and biotechnology , tau pathology , antibody , alzheimer's disease , biology , pathology , disease , medicine , immunology
underwent a thorough ophthalmological assessment at the first visit, and baseline imaging with the SLO. After 5 days of 180mg oral curcumin (Theracurmin , 3 capsules/day), imaging with the SLO was repeated. SLO scanning was performed with three excitation wavelengths in order to separate autofluorescence from curcumin fluorescence. Retinal SLO-images were assessed visually. Results:Baseline autofluorescence images (BAF) showed no alterations in both AD-patients and controls. Multispectral imaging at three wavelengths showed no plaque-like alterations in the retina neither at baseline nor after 5 days of curcumin intake (AD figure 1, Control figure 2). Conclusions:Based on a visual assessment of retinal SLO images, no obvious differences before and after curcumin supplementation were observed in this small cohort of EOAD patients. This may be a result of 1. insufficient uptake of curcumin, 2. a low curcumin signal to autofluorescence ratio and/or 3. absence of retinal amyloid in (this subset of) AD patients. We will perform quantitative analysis of the retinal images and expand the cohort with a higher dose of curcumin in order to further investigate the possibility of retinal imaging for amyloid detection.